- Company
- Pfizer's Vizimpro can be prescribed at general hospitals
- by Eo, Yun-Ho Feb 3, 2021 06:09am
- Pfizer's EGFR TKI and Vizimpro are now available in general hospitals with insurance benefits. According to related industries, Vizimpro (Dacomitinib monohydrate), a second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), listed in December. It passed the drug committee (DC) of general hospitals such as I
- Company
- Menarini Korea presents Fulcare's digital campaign video
- by Feb 3, 2021 06:09am
- Menarini Korea (CEO Hyeyoung Park) announced on the 2nd that it is releasing a new digital campaign video 'Re, Start Again' of Fulcare, a treatment for nail athlete's foot. The new campaign was planned as part of Fulcare's brand campaign 'Clear Again' from 2020. By emphasizing the keyword 'again' by focusing on 're' at the back of Fulcare
- Company
- Profitable lazertinib makes 5-year income for Oscotec
- by An, Kyung-Jin Feb 2, 2021 06:25am
- For last couple of years, Oscotec has generated 57 billion won from licensing out a new drug candidate. The South Korean company earned more than five years of income by selling a profitable new drug candidate to Yuhan Corporation. On Jan. 26, Oscotec announced Yuhan Corporation would pay out USD 22.1 million (approximately 24.8 billion
- Company
- COX-2 inhibitors recover and grow 56% in 5 years
- by Kim, Jin-Gu Feb 2, 2021 06:25am
- The prescription volume of cyclooxygenase-2 (COX-2) inhibiting nonsteroidal anti-inflammatory drugs (NSAIDs) seems to be increasing rapidly. A major product Celebrex (celecoxib) had its pricing cut by half after its patent was expired in 2015, but the prescription volume soared by 56 percent in five years until last year. The industry expert
- Company
- MSD Korea reaches collective agreement with union
- by Feb 2, 2021 06:25am
- MSD Korea (CEO Kevin Peters) announced the company reached a collective agreement with the labor union on Jan. 28 before fully splitting off Organon Korea. This marks the first collective agreement settled since the establishment of MSD Korea Labor Union. And the company noted that it was a mutual collaborative outcome of the management
- Company
- KRPIA appoints Oh Dong-wook Chairman & new BOD is launched
- by Eo, Yun-Ho Feb 1, 2021 06:16am
- Along with the appointment of a new chairman, there have been significant changes in the KRPIA’s BOD. On the 27th, the KRPIA announced that, after Avi BenShoshan, former CEO of MSD Korea, Oh Dong-wook, CEO of Pfizer Korea, was elected as the 14th chairman and will lead the association from February 2021. The KRPIA plans to newly launch
- Company
- Daewoong & Roche were selected as Best Companies to Work for
- by Eo, Yun-Ho Feb 1, 2021 06:15am
- This year, many healthcare companies were listed as one of the top 100 companies to work for. According to related industries, companies such as Daewoong, Roche Diagnosis, Baxter, and Medtronic were selected as the 'Best Companies to Work for in Korea 2020' hosted by the global HR consulting firm GPTW Institute (Great Place to Work Institu
- Company
- Disappointing result of first 2021 Cancer Committee meeting
- by Eo, Yun-Ho Jan 29, 2021 06:14am
- The National Health Insurance (NHI) reimbursement expansion on the indication targeting ‘all-comer’ and a combined targeted therapy would have to wait for another time. The Health Insurance Review and Assessment Service (HIRA) Cancer Deliberation Committee convened a first meeting of the year yesterday, and they decided the coverage o
- Company
- KRPIA appoints new Chair Oh Dongwook of Pfizer Korea
- by Eo, Yun-Ho Jan 29, 2021 06:14am
- On Jan. 27, Korean Research-based Pharmaceutical Industry Association (KRPIA) announced Country Manager Oh Dongwook of Pfizer Pharmaceutical Korea is appointed as he 14th Chair of KRPIA leading the organization from February 2021. The new chair was elected as a member of the board in January 2016, and has been contributing in pushing KRPI
- Company
- Going beyond antidiabetic, Forxiga to treat heart failure
- by Jan 28, 2021 05:59am
- AstraZeneca’s Forxiga has been approved in South Korea to treat diabetes and heart failure. The indication is obtained for the first time for a sodium-glucose co-transporter-2 (SGLT2) inhibitor. The industry experts noted, “Forxiga demonstrated reduction of cardiovascular death risk and hospitalization for heart failure in patients wit
